H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Kala Pharmaceuticals to $15 following the company’s Q3 results but reiterates a Buy rating on the shares. The analyst adjusted his 2019 revenue projections lower due to the time needed for commercial payors to start covering Inveltys. Further, due to recent late-stage trial initiations of competitor candidates in dry eye, the analyst more than halved his projected peak annual sales of KPI-121 0.25% from over $2B to $1B, while maintaining the probability of success at 65%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.